Background: Case-fatality rates are important for assessing the risks and benefits of
anticoagulation in patients with venous thromboembolism (VTE). Purpose: To summarize …

In patients with venous thromboembolism (VTE), assessment of the risk of fatal recurrent
VTE and fatal bleeding during anticoagulation may help to guide intensity and duration of …

ContextPatients with venous thromboembolism (VTE) are susceptible to recurrent events,
but whether prolonging anticoagulation is warranted in patients with VTE remains …

Background: Clinicians should consider the clinical impact of anticoagulant-related bleeding
when deciding on the duration of anticoagulant therapy in patients with venous …

Background The long‐term risk for recurrent venous thromboembolism (VTE) during
extended anticoagulation for a first unprovoked VTE is uncertain. Objectives To determine …

Background In patients with venous thromboembolism (VTE), identifying clinical risk factors
for recurrence during the initial 3 months of anticoagulant therapy and knowledge of the time …

Pinede L, Duhaut P, Cucherat M, Ninet J, Pasquier J, Boissel JP (Hôpital Edouard Herriot
and Unité de Pharmacologie Clinique, Lyon, France). J Intern Med 2000; 247: 553–562 …

Background: The long-term risk for fatal pulmonary embolism (PE) after treatment of venous
thromboembolism (VTE) may be an important factor in the decision to discontinue this …

Background: Fatal bleeding is a serious consequence of anticoagulant therapy, but factors
associated with fatal bleeding during the first 3 months of treatment of venous …

Background: The long-term risk for major bleeding in patients receiving extended (beyond
the initial 3 to 6 months) anticoagulant therapy for a first unprovoked venous …